News

New mutations found in the GNPTG gene were identified as the underlying cause of a familial form of a scleroderma-like disease, according to a study published in the journal Pediatric Rheumatology. The study, “Next Generation Sequencing identifies mutations in GNPTG gene as a cause of familial form…

A new treatment using adipose-derived regenerative cells (ADRCs) to treat hand problems caused by scleroderma is now available at Okyanos Center for Regenerative Medicine in Freeport, Grand Bahama. Researchers developed the treatment protocol based on the STAR clinical study sponsored by Cytori Therapeutics. “Through the delivery of regenerative…

Urinary symptoms are frequent in patients with systemic sclerosis (SSc), especially in patients with limited cutaneous SSc, which have a 2.2 times higher risk of developing urinary symptoms than other SSc patients, and in patients who are positive for anti-centromere antibodies, who have a 2.8 times increased risk. Findings…

The innate immune system and small RNA molecules known as microRNA are key factors in the development of scleroderma, according to a study based on previously published research. The study, “Inflammasome lights up in systemic sclerosis,” was published in the journal Arthritis Research & Therapy. The…

Viracept (nelfinavir mesylate, NFV), an antiretroviral drug approved as a therapy against the human immunodeficiency virus (HIV), could be beneficial in the treatment of systemic sclerosis (SSc), a study on a mouse model of the disease shows. The study, “The Antiretroviral nelfinavir mesylate, a potential therapy for systemic scleroderma,”…

Scleroderma Canada and the Pulmonary Hypertension Association of Canada have collected more than 2,000 letters signed by pulmonary arterial hypertension (PAH) patients, their caregivers and loved ones urging politicians to make all PAH treatments accessible as soon as possible through public funding. Health Canada approved Actelion’s Uptravi (selexipag) in January…

The World Scleroderma Foundation (WSF) will host the 5th Systemic Sclerosis World Congress from Feb. 15-17, 2018, in Bordeaux, France. All meeting attendees will have the opportunity to get together at the Bordeaux Congress Centre to share their knowledge and latest discoveries about systemic sclerosis (SSc). Registration to attend the meeting…

Results from a multicenter clinical trial in Belgium further demonstrated the therapeutic effects of rituximab, marketed by Genentech under the name Rituxan, to treat early diffuse cutaneous systemic sclerosis (dcSSc). The treatment not only improved skin symptoms but also prevented disease progression. The results were discussed in…

Inventiva Pharma, which develops therapies for fibrotic diseases, said the World Health Organization (WHO) has granted the International Non-Proprietary Name lanifibranor for IVA337. Lanifibranor is Inventiva’s lead drug candidate now being investigated to treat systemic sclerosis (SSc) and non-alcoholic steatohepatitis (NASH). The anti-fibrotic drug functions by activating three isoforms of…

Mycophenolate mofetil stabilizes the lung function of patients with systemic sclerosis-associated interstitial lung disease, or SSc-ILD, a study confirms. The stabilization occurs even when the therapy, whose short name is MMF, is administered in doses lower than those used in a previous Phase 2 clinical trial. The latest study is retrospective, which…